PFIZER INC.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.

Pfizer's Phase 2 study of ponsegromab, targeting GDF-15 in cancer cachexia, met primary endpoint of weight gain vs. placebo. Results showed significant improvements in body weight, muscle mass, quality of life, and physical function with no significant adverse effects. Data presented at ESMO 2024 and published in NEJM, suggesting a potential breakthrough treatment for cachexia.

Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.

FDA approves Roche's OCREVUS ZUNOVO™ with Halozyme's ENHANZE® for RMS and PPMS, offering a 10-minute subcutaneous injection.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

Moderna acknowledges slower-than-expected uptake of its RSV vaccine, mResvia, amid competition from GSK and Pfizer. The company adjusts its market expectations and financial guidance, cutting R&D spending and discontinuing several pipeline projects. Moderna plans to focus more on oncology and respiratory disease vaccines, aiming to launch five new products by 2027.

Moderna delays break-even goal to 2028, predicting 2025 sales below current year forecast, due to extended regulatory timelines for flu and cancer vaccines. Shares drop 17.1% to $65.88. Expects $2.5B-$3.5B in 2025 sales, below analyst forecast of $3.74B. Plans to submit FDA applications for RSV and COVID-influenza combo shots.

Valneva SE announces successful pricing of €61,180,000 Private Placement, aiming to fund clinical programs and future growth, including the Shigella vaccine program. The company expects to have sufficient resources until potential milestone and commercial revenues from its Lyme disease program enable sustained profitability.

The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), Yale University as top non-industry, Johnson & Johnson as top industry, and CNS as top therapy area (92%). The US leads in trials, and Phase II trials dominate since 2013.

The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), with Yale University and Johnson & Johnson as top sponsors. Central nervous system trials dominate (92%), with depression as the top indication. The US leads in North American studies, and Phase II trials have outnumbered others since 2013.